This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (19)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Cardiovascular System  • Arrhythmias  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Do We Know Enough?

Arch Gen Psychiatry. 2001;58:1168-1171.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

ANTIPSYCHOTIC drugs have revolutionized the treatment of psychotic and mood disorders since their introduction 50 years ago. Although psychiatric patients have significantly benefited from the use of typical antipsychotic drugs, their limitations have become apparent and include extrapyramidal symptoms and tardive dyskinesia. The next generation of antipsychotic drugs (novel or atypical) offers advantages compared with the typical antipsychotic drugs: they are uniformly better tolerated and are more efficacious in certain symptom domains. However, current data do not suggest that these new medications offer advantages regarding cardiovascular adverse effects.¹

To ascertain the safety profile of new drugs, phase 2 and phase 3 clinical trials are conducted and typically involve the study of several hundred patients. However, rare or idiosyncratic adverse effects missed during phase 2 or 3 trials may become apparent only after the drug is released onto the market. Sudden death in psychiatric patients treated with antipsychotic drugs has been . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Antipsychotics and the Risk of Sudden Cardiac Death
Wayne A. Ray, Sarah Meredith, Purushottam B. Thapa, Keith G. Meador, Kathi Hall, and Katherine T. Murray
Arch Gen Psychiatry. 2001;58(12):1161-1167.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cardiovascular Effects of Noncardiovascular Drugs
Raj et al.
Circulation 2009;120:1123-1132.
FULL TEXT  

Minimal-medication approaches to treating schizophrenia
Calton and Spandler
Adv. Psychiatr. Treat. 2009;15:209-217.
ABSTRACT | FULL TEXT  

Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death
Ray et al.
NEJM 2009;360:225-235.
ABSTRACT | FULL TEXT  

Association of antipsychotic and antidepressant drugs with Q-T interval prolongation
Zemrak and Kenna
Am J Health Syst Pharm 2008;65:1029-1038.
ABSTRACT | FULL TEXT  

A Systematic Review of the Soteria Paradigm for the Treatment of People Diagnosed With Schizophrenia
Calton et al.
Schizophr Bull 2008;34:181-192.
ABSTRACT | FULL TEXT  

Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data
Hennessy et al.
BMJ 2002;325:1070-1070.
ABSTRACT | FULL TEXT  

Antipsychotics and sudden death: is thioridazine the only bad actor?
RAY and MEADOR
Br. J. Psychiatry 2002;180:483-484.
FULL TEXT  

Neuroleptics and Sudden Cardiac Death
JWatch Psychiatry 2002;2002:4-4.
FULL TEXT